The purpose of this study is to investigate the
use of the medication Ondansetron as an adjunctive or add-on therapy to
existing anti-psychotic medication in the treatment of schizophrenia
symptoms. Ondansetron is a well established medication which is approved
in Australia for the treatment of drug-induced nausea and vomiting.
However, various case studies and clinical studies have shown
Ondansetron to also be effective in the treatment of symptoms associated
with persistent schizophrenia.
(Formerly known as Central Clinical School)
Showing posts with label Daniel Grice. Show all posts
Showing posts with label Daniel Grice. Show all posts
27 Mar 2014
Participants sought: Investigating Ondansetron for chronic residual schizophrenia
The purpose of this study is to investigate the
use of the medication Ondansetron as an adjunctive or add-on therapy to
existing anti-psychotic medication in the treatment of schizophrenia
symptoms. Ondansetron is a well established medication which is approved
in Australia for the treatment of drug-induced nausea and vomiting.
However, various case studies and clinical studies have shown
Ondansetron to also be effective in the treatment of symptoms associated
with persistent schizophrenia.
Participants sought: An adjunctive pro-cognitive treatment in schizophrenia
Website link: http://www.maprc.org.au/psychopharmacology
Ethics Committee Project Number: 110/13
Subscribe to:
Posts (Atom)
